Already one prospective clinical trial is under way to establish HRD score for selecting appropriate patients with ovarian cancer for treatment with the PARP inhibitor, rucaparib (ClinicalTrials.gov ID: NCT01891344), and equivalent studies will be carried out as exploratory analyses in TNBCs or BRCA1/2-related breast cancers. Here, BRCA1 is linked to breast cancer.